Were the EMPA-REG Renal results chance, or is this a class effect? Let's take a deep dive into CANVAS, published in the NEJM recently, which examined the cardiovascular safety of canaglifozin in type 2 diabetes.
Background
This week, we will discuss the MENTOR trial, which pitted rituximab versus cyclosporine for membranous nephropathy
Background
This week, we will discuss an RCT, a pediatric RCT, and a pediatric RCT in childhood nephrotic syndrome! A trial that asks a question of burning importance to the management of childhood nephrotic syndrome. Join us as we tackle PREDNOS.
Background
Atrosentan makes a return visit to NephJC, but now it goes beyond changes in proteinuria and shows improved kidney outcomes. Is it enough to overcome the fluid complications?
Background
This week, we will discuss a risk score which helps to prognosticate the most common glomerular disease. Not only is IgA most common - it is quite heterogeneous, which makes the problem of who should get treated quite difficult.
